Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 3
Tests a shorter course of immunotherapy in people with advanced lung cancer
Tests stopping immunotherapy early in adults with advanced non-small cell lung cancer.
Key facts
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Where
- 's-Gravenhage, Amsterdam, Apeldoorn, Dirksland, Dordrecht, and Leiden, NetherlandsSee the 6 sites
- Trial code
- Registry title
- A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 500 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 1 Aug 2031
- Type of study
- Interventional
- Record updated
- 12 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV (metastatic) non-small cell lung cancer. They must have had about 6 months of first-line immunotherapy, with or without chemotherapy, and the cancer has not grown.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced, metastatic non-small cell lung cancer, UICC stage IV
- Earlier treatment
- Must have had first-line immunotherapy or first-line chemo-immunotherapy for 6 months (plus or minus 2 weeks). No other systemic anti-cancer treatment for this disease.
Main reasons for not taking part
- Other systemic anti-cancer treatment for this disease besides first-line (chemo-)immunotherapy
- Any contraindication (as per label) for immune checkpoint inhibitors
- Cancer that has grown: response or stable disease is required, on imaging no older than 3 weeks
- ECOG performance status above 2, or not fit and willing to continue treatment
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Advanced, metastatic non-small cell lung cancer UICC stage IV
- Having received first line immunotherapy or first line (chemo)immunotherapy for 6 months ±2 weeks
- Response or stable disease according to RECIST 1.1 as determined by imaging no older than 3 weeks at moment of randomization
- Signed and dated informed consent
- ECOG PS 0-2 and fit and willing to continue treatment with first line (chemo-)immunotherapy as deemed by the treating physician
Who cannot take part
- Any contra-indication (as per label) for treatment with immune checkpoint inhibitors
- Other systemic anti-cancer treatment for the disease under study other than the first line (chemo-)immunotherapy
Where in Netherlands
- Haga Hospital's-Gravenhage, NetherlandsNot yet recruiting
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting
- Gelre HospitalsApeldoorn, NetherlandsNot yet recruiting
- Het Van Weel-Bethesda ZiekenhuisDirksland, NetherlandsNot yet recruiting
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsNot yet recruiting
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the efficacy of shorter duration of standard of care treatment ([chemo]immunotherapy) for patients with metastatic NSCLC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
- Plain-language title
- Tests a shorter course of immunotherapy in people with advanced lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 September 2025